Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Art Bechhoefer who wrote (2540)	4/12/1999 4:55:00 PM
From: Mike McFarland	Read Replies (2) \| Respond to of 4676

a new subsidiary of Isis... Isis and Elan Form Partnership to Develop Oral Antisense Drugs; TNF-alpha Inhibitor Is First Drug Candidate biz.yahoo.com Elan will make a $27 million equity investment in Isis, consisting of $15 million of common stock purchased at a premium to market and $12 million of convertible exchangeable preferred stock. Elan will also receive warrants exercisable in five years. Elan has the right to convert the preferred stock into either an ownership interest in Isis or in the new subsidiary. _________ I have just started looking into Isis, I spent a couple hours reading the theads etc...and here is a summary of the sense of things...all imho Message 8845222 If anybody wants to comment...please do so.